{"id":"W3134908202","doi":"10.1200/jco.2021.39.6_suppl.269","title":"Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Everolimus; Renal cell carcinoma; Clinical endpoint; Sunitinib; Progression-free survival; Oncology; Clinical trial; Urology; Confidence interval; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002010901,0.001433162,0.002130441,0.0003554488,0.0004413705,0.0008930958,0.001052116,0.001172258,0.007515701],"category_scores_gemma":[0.001389697,0.0005902098,0.001609708,0.0003886651,0.0007918971,0.0009232527,0.0004254889,0.003779783,0.001150078],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009224073,"about_ca_system_score_gemma":0.001863071,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001206694,"about_ca_topic_score_gemma":0.003839936,"domain_scores_codex":[0.9993825,0.0003956503,0.00002374058,0.00008588585,0.00004502691,0.00006723089],"domain_scores_gemma":[0.9992191,0.0002029102,0.0001777416,0.0000482685,0.00003963595,0.0003123871],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9507422,0.01236865,0.001695976,0.0007917843,0.001309751,0.0001002838,0.0001018423,0.001013328,0.005936245,0.0001664332,0.003711362,0.02206212],"study_design_scores_gemma":[0.9215265,0.07225625,0.003041025,0.00003363387,0.0004533347,0.00008130517,0.00002104382,0.0006336796,0.0005381381,0.0001777982,0.001224046,0.00001311905],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9720052,0.004686476,0.001196914,0.001632599,0.0004195213,0.009253644,0.006166288,0.0002791943,0.0043601],"genre_scores_gemma":[0.9745129,0.002553143,0.003122135,0.002056899,0.0003245852,0.007764685,0.004705024,0.0000642845,0.004896329],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007515701,"threshold_uncertainty_score":0.02514249,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1826300684046734,"score_gpt":0.4608497912217678,"score_spread":0.2782197228170944,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}